Ix

Harley-Davidson 2022 Investor Day Update: Hardwire Stage II

Retrieved on: 
Tuesday, May 10, 2022
Harley-Davidson, Acceleration, Business, Population, HD, Rollcage Stage II, Private Securities Litigation Reform Act, Part, Harley-Davidson Museum, Harley-Davidson LiveWire, Company, NYSE, Capital expenditure, WI, Hardwire, LW, HDI, Lists of companies, Prospectus, Clothing, Ix, Risk, Annual report, HDFS, Livewire, Lists of disasters, HDMC, Uncertainty, Vii, ABIC, Language, CAGR, SEC, Goal, CEO, The Beatles' 1964 North American tour, Multimedia, Medical device, Animal, Pet, Public relations, Risk management, Motorcycle, EU

MILWAUKEE, May 10, 2022 /PRNewswire/ -- Harley-Davidson, Inc. ("Harley-Davidson") (NYSE:HOG) will host its 2022 Investor Day at the Harley-Davidson Museum in Milwaukee, WI today.

Key Points: 
  • MILWAUKEE, May 10, 2022 /PRNewswire/ -- Harley-Davidson, Inc. ("Harley-Davidson") (NYSE:HOG) will host its 2022 Investor Day at the Harley-Davidson Museum in Milwaukee, WI today.
  • "In motorcycling, when you want to get more out of an engine, you upgrade it by adding a Stage II kit, that is what we are doing with our Hardwire strategy, tuning the engine of our business for improved acceleration and increased performance."
  • This press release relates to the company's strategic plan, The Hardwire, including Hardwire Stage II.
  • Therefore, investors should construe these statements regarding The Hardwire and Hardwire Stage II only as goals, aims, and objectives rather than promises of future performance or absolute statements.

Dalata Hotel Group PLC: Holding(s) in Company

Retrieved on: 
Tuesday, May 10, 2022
Council Implementing Regulation (EU) No. 282/2011, Central Bank of the Republic of Turkey, Disclosure, Acquisition, Person, Ix, Letter, EC, Intention, Vii, Central bank, LEI, Life, Exercise, Security (finance), Auction, Medical device, EU, Regulation, Transparency

In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

Key Points: 
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    i.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

Retrieved on: 
Monday, May 9, 2022
Alternative Medicine, Health, Fitness & Nutrition, General Health, Pharmaceutical, Biotechnology, Exercise, U.S. Securities and Exchange Commission, COVID 19, Forward-looking statement, Defecation, Diet, Xi, Allergy, Twitter, Failure, Absorption, 100,000, Cellulose, Gel, New, Company, NYSE, Flatulence, Abdomen, Diarrhea, Functional constipation, Use, Patient, COVID, Security (finance), GLS, Webcast, Pain scale, FDA, Ix, Non-alcoholic fatty liver disease, Annual report, Incidence, Food, Obesity, Environment, BMI, NAFLD, Type 2 diabetes, Body mass index, Adoption, Gelatin, Citric acid, NASH, Liver, Growth, Risk, Human, Nature, Dietary supplement, Risk management, Hydrogel, Nitenpyram, Gelesis

Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on May 12, 2022 following the market close.

Key Points: 
  • Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on May 12, 2022 following the market close.
  • The live conference call webcast can be accessed on the Gelesis Investor Relations website at https://ir.gelesis.com/ .
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

A Bold New World: GE Healthcare’s Pioneering Deep Learning Image Reconstruction Technology Benefits More Than 2 Million Patients Globally

Retrieved on: 
Friday, May 6, 2022
Other Health, Software, General Health, Radiology, Oncology, Data Management, Medical Devices, Technology, Hospitals, Surgery, Other Technology, Health, Neurodegeneration, GE Healthcare, International Society for Magnetic Resonance in Medicine, CE, Hospital, Artificial intelligence, Cancer, Solution, CEO, AI, Annual general meeting, AIR, Ecosystem, MRI, Twitter, Deep learning, Hospitality Review, NYSE, Hospital for Special Surgery, Patient, U.S. News & World Report, FDA, Ix, Claustrophobia, Frost & Sullivan, LinkedIn, ROI, News, Mark (given name), MR, Magnetic resonance, Efficiency, Anatomy, Sale, Thomas Edison, Man, COVID-19, Prostate cancer, Signal-to-noise ratio, Stanford University, Radiation, Paediatric radiology, CT, Diagnosis, SNR, Noise, International Society, Wind, Medical imaging, Medicine, Pharmaceutical industry, Medical device, EU, Kaylee, Facebook

This marks a significant moment in the democratization of artificial intelligence (AI) and deep learning for the benefit of healthcare systems and patients around the world.

Key Points: 
  • This marks a significant moment in the democratization of artificial intelligence (AI) and deep learning for the benefit of healthcare systems and patients around the world.
  • Since we first saw the power of our AI-based deep learning image reconstruction technology, AIR Recon DL, we knew it could have a massive clinical impact.
  • With this expansion, AIR Recon DL covers nearly 90 percent of clinical MR sequences, regardless of the anatomy being scanned.
  • These advancements have proved especially valuable for those who struggle to remain still during MR exams, such as pediatric, neurodegenerative and geriatric patients.

Dalata Hotel Group PLC: Holding(s) in Company

Retrieved on: 
Friday, May 6, 2022
Council Implementing Regulation (EU) No. 282/2011, Central Bank of the Republic of Turkey, Disclosure, Acquisition, Person, Ix, Letter, EC, Intention, Vii, Central bank, LEI, Life, Exercise, Security (finance), Auction, Medical device, EU, Regulation, Transparency

In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

Key Points: 
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    i.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).

SIGA Reports Financial Results for Three Months Ended March 31, 2022

Retrieved on: 
Thursday, May 5, 2022
Xi, Development, Infection, Contract, Human, Annual report, Monkeypox, SIGA Technologies, Vii, Risk, Smallpox, Forward-looking statement, Immune system, European Medicines Agency, Director, Company, Immunotherapy, Neoplasm, FDA, Ix, Meridian Medical Technologies Inc., Executive order, Government, Health Canada, Research, Public Health Agency of Canada, Vaccinia, Income, Private Securities Litigation Reform Act, EMA, Policy, Genome, Time, CMOS, MAA, Vaccine, IV, PHAC, Protein, Documentation, Exercise, Board, BARDA, COVID-19, Food, Cancer, Patent, Investor relations, Phrase, Conference, Vaccination, Public Health Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Cowpox, Construction, Pharmaceutical industry, Meridian, EU

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2022.

Key Points: 
  • The special dividend is payable on June 2, 2022 to shareholders of record at the close of business on May 17, 2022.
  • In January 2022, the European Medicines Agency(EMA) approved the marketing authorisation application (MAA) for oral Tecovirimat SIGA, the same formulation that was approved by theU.S.
  • In January 2022, SIGA announced a research collaboration with Bioarchitech, aUnited Kingdom-based biotech company developing immunotherapy for the treatment of cancer.
  • During the first quarter of 2022, SIGA repurchased approximately 1.0 million shares of its common stock, for approximately $6.6 million.

Maravai LifeSciences Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Earnings per share, Cyprus Securities and Exchange Commission, Income, Investment, Forward-looking statement, GAAP, EBITDA, LLC, Accounting, Tax, Biotechnology, ASC, Safety, Security (finance), Depreciation, Ix, Annual report, Adoption, Class, Private Securities Litigation Reform Act, Vaccine, Sale, Vii, Melamaravakkadu, EPS, Research, Insurance, Bank, Pharmaceutical industry, Fine chemical

(9) Represents income tax benefits at Maravai LifeSciences Holdings, Inc. related to the income tax treatment of income derived from sales to foreign-domiciled customers.

Key Points: 
  • (9) Represents income tax benefits at Maravai LifeSciences Holdings, Inc. related to the income tax treatment of income derived from sales to foreign-domiciled customers.
  • The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.
  • ET to discuss its financial results for the first quarter of fiscal year 2022.
  • Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.

SIGA Declares Special Dividend of $0.45 Per Share

Retrieved on: 
Thursday, May 5, 2022
Board, BARDA, COVID-19, Optimism, Smallpox, Contract, Forward-looking statement, Private Securities Litigation Reform Act, Xi, EMA, NASDAQ, GLOBE, Development, Director, Company, Policy, Risk, FDA, Ix, Human, Annual report, Patent, SIGA Technologies, Government, Phrase, Vaccine, Vii, IV, Health Canada, Vaccination, Infection, CEO, Research, Documentation, Exercise, Pharmaceutical industry

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.

Key Points: 
  • NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.
  • The special dividend is payable on June 2, 2022 to shareholders of record at the close of business on May 17, 2022.
  • Phil Gomez, CEO of SIGA, commented, Based on the Companys current cash resources and its strong balance sheet, we believe it is an appropriate time to declare a special dividend.
  • The special dividend declaration reflects confidence from the financial performance of SIGA in 2020 and 2021, as well as optimism about the Companys business prospects going forward.

ScoutCam Unveils New Website Reflecting Heightened Focus on Visualization Solutions for the Fast Growing I4.0 Markets

Retrieved on: 
Tuesday, May 3, 2022
Condition, COVID-19, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Xi, GLOBE, Company, Aviation, Legislation, Security (finance), Coronavirus, Ix, Overalls, Trademark dilution, Compliance, OTCQB, Marketing, Pandemic, Sale, Vii, SEC, Solution, News, Terminology, Transport, AI, Oxide, Maintenance (technical), Online shopping, Risk management, Maintenance, Industry

OMER, Israel, May 03, 2022 (GLOBE NEWSWIRE) -- ScoutCam (OTCQB: SCTC), a leading provider of image based solutions (including cloud and AI image processing) to the Condition Based Maintenance and the Predictive Maintenance markets, as well as a leading provider of image based solutions to the medical device market, announced today the launch of its updated website.

Key Points: 
  • The new website marks the evolution of ScoutCam both inside the company and how it presents to the outside world, with a fresh strategy focused on the global Industry 4.0 markets and the changing environment, said Yovav Sameah, Chief Executive Officer.
  • ScoutCam is pioneering the Predictive Maintenance and Condition Based Monitoring markets with its visualization and AI platform.
  • Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
  • For more information on ScoutCam and to view the updated site, please visit www.scoutcam.com .

Cairn Homes Plc: Holding(s) in Company

Retrieved on: 
Tuesday, May 3, 2022
Council Implementing Regulation (EU) No. 282/2011, Central Bank of the Republic of Turkey, Disclosure, Person, Acquisition, Ix, Letter, EC, Intention, Vii, Central bank, LEI, Life, Exercise, Security (finance), Online gambling, Auction, Medical device, EU, Regulation, Transparency

In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

Key Points: 
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    Done at London on 29/04/2022.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).